---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-029657"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:45:39.172330+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar reports tumor reduction in Phase 1b camsirubicin trial for advanced soft tissue sarcoma at CTOS

## Summary
- 14 patients enrolled across 5 dose cohorts; 9 of 14 had stable disease per RECIST 1.1.
- All patients in cohorts 4 and 5 achieved stable disease; 3 most recent showed ~20% tumor reduction.
- One patient with unresectable cancer became eligible for resection after tumor reduction and underwent successful surgery.
- No dose-limiting toxicity observed; MTD not yet reached; one LVEF decrease in medically complex patient is being monitored.

## SEC filing metadata
- accession: 0001437749-23-029657
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/0001437749-23-029657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/mnpr20231030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-029657
- JSON: https://secwatch.observer/filing/0001437749-23-029657.json
- Plain text: https://secwatch.observer/filing/0001437749-23-029657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.